tbuckley/cabot-search huggingface dataset:
Problematic Strength of the Association Between Atopic Dermatitis and Suicidality—Reply
Authors: Kevin K. Wu, Thanh-Lan Bui, April W. Armstrong
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
A 3D cell printed muscle construct with tissue-derived bioink for the treatment of volumetric muscle loss
Authors: Yeong-Jin Choi, Young-Joon Jun, Dong Yeon Kim, Hee-Gyeong Yi, Su-Hun Chae, Junsu Kang, Juyong Lee, Ge Gao, Jeong-Sik Kong, Jinah Jang, Wan Kyun Chung, Jong-Won Rhie, Dong-Woo Cho
Journal: Biomaterials (2019)
The effect of influenza vaccination on airway responsiveness in patients with stable asthma
Authors: S. J. Bourke, D. W. Reid, C. L. Bromly, N. Leitch, S. C. Stenton, D. J. Hendrick
Journal: Thorax (1996)

Infection with influenza A virus causes exacerbations of asthma and increased airway responsiveness (AR). Annual vaccination is recommended. Live vaccines and some older killed vaccines caused increased AR. More recent studies using purified sub-unit vaccines suggest no effect on AR but some patients report exacerbations of asthma and there is reluctance to adhere to vaccination recommendations. There is therefore a need for further studies of the effect of current vaccines on AR and asthma control. We studied 22 subjects (mean age 41 (range 19-71) years; 8 male) with mild (FEV, > 60% predicted) stable asthma. All were taking inhaled β agonists and 20, inhaled steroids; 13 had previously had influenza vaccination. Subjects were randomized to receive placebo (n = 5) or inactivated surface antigen vaccine (Evans Ltd) (n=17). They kept records of asthma symptoms, medication used and adverse events. FEV and AR (as the dose of methacholine provoking a 20% fall in FEV : PD) were measured twice before vaccination and at 48 and 96 hours post vaccination. There was no significant difference in pre and post vaccination FEV or AR in either the placebo or vaccinated groups: mean FEV changed from 2.9L pre vaccine to 2.83 and 2.9L, 48 and 96 hours post vaccine; mean PD changed from 120μg pre vaccine to 102 and 101 μg, 48 and 96 hours post vaccine. No subject showed a significant fall in FEV or PD, or had a change in asthma symptoms or medication; 7 of those given vaccine had fever and malaise, and one had a local reaction. We conclude that inactivated surface antigen vaccine does not generally exert any adverse effect on asthma.
FLT3N676K drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis
Authors: Axel Hyrenius-Wittsten, Mattias Pilheden, Antoni Falqués-Costa, Mia Eriksson, Helena Sturesson, Pauline Schneider, Priscilla Wander, Cristian Garcia-Ruiz, Jian Liu, Helena Ågerstam, Anne Hultquist, Henrik Lilljebjörn, Ronald W. Stam, Marcus Järås, Anna K. Hagström-Andersson
Journal: Leukemia (2019)
Response to: ‘Inflammatory and non-inflammatory triggers of acute coronary syndromes’ by Eyuboglu
Authors: Helga Westerlind, Marie Holmqvist, Lotta Ljung, Thomas Frisell, Johan Askling
Journal: Annals of the Rheumatic Diseases (2019)

We thank Dr Eyuboglu for his comments1 on our article ‘Siblings of rheumatoid arthritis patients are at increased risk for acute coronary syndrome’.2 

Familial risks tell us if risk factors for a disease are shared within families. By studying familial risks, we can also investigate shared susceptibility between diseases. In our present study, we have, by using the full siblings of patients with rheumatoid arthritis (RA), created a study population that are enriched for both the genetic and (familial) environmental risk factors involved in RA. If any disease has an increased frequency in our …
Abstract 5441: The Roles for MicroRNA-221 and IGF-1 Signaling in Regulation of High Glucose-Induced Endothelial Dysfunction and Apoptosis
Authors: Yangxin Li, Yao-Hua Song, Fan Li, Kate McNamara, Yong-Jian Geng
Journal: Circulation (2008)

Persistent hyperglycemia represents a major metabolic complication of diabetes, which may cause endothelial cell dysfunction and apoptosis. microRNAs are novel biomarkers, modulators and therapeutic targets for disease. The microRNA miR-221 is expressed in human umbilical vein endothelial cells (HUVEC). Insulin-like growth factor 1 (IGF-1) is an important survival factor for multiple cell types. This study was to investigate whether high glucose (HG) induces endothelial dysfunction and apoptosis through altering the microRNA expression and IGF-1 signaling. The mirVana qRT-PCR miRNA detection assay showed that exposure to glucose for 24 h dose-dependently (up to 25 mM) increased miR-221 expression by 2.6 ± 0.5 folds (p&lt;0.05). HG treatment decreased c-kit protein expression (58 ± 7 % decrease vs. control at 48 h) assessed by flow cytometry. The treated HUVEC had a reduced capacity for wound healing responded to stem cell factor (SCF, the ligand of c-kit). SCF-induced HUVEC migration potential was also reduced significantly by exposure to high dose of glucose. As estimated by prediction algorithms, c-kit, but not IGF-1, was identified as the target of miR-221. Transfection of HUVEC with 2′-O-methyl antisense inhibitory oligonucleotide (AMO-221) downregulation of miR-221 led to attenuation of the glucose’s effect on the c-kit expression, SCF-induced migration and wound healing in HUVEC. Prolonged glucose exposure (25 mM, 96 h) induced apoptosis of HUVEC assessed by Death ELISA (O.D. values = 0.49 ± 0.06 in glucose group vs. 0.12 ± 0.07 in control, p&lt;0.01). Addition of IGF-1 (30 ng/ml) blocked the glucose-induced apoptosis, whereas AMO-221 did not attenuate the apoptosis. In addition, the anti-apoptotic effects of IGF-1 was attenuated by PI3 kinase inhibitor LY294002 (15 uM) (IGF-1 + glucose + PI3 kinase inhibitor vs. IGF-1 + glucose = 0.45 ± 0.07 vs. 0.15 ± 0.05 O.D. values). Our data demonstrate that downregulation of miR-221 attenuates HG-induced reduction of c-kit, wound healing and migration of HUVEC, and enhanced IGF-1 signaling prevents HG-induced apoptosis. Thus, reducing miR-221 expression and activating IGF-1 signaling pathway may be a useful strategy to prevent diabetic-induced endothelial dysfunction and apoptosis. This research has received full or partial funding support from the American Heart Association, AHA South Central Affiliate (Arkansas, New Mexico, Oklahoma &amp; Texas).
Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study
Authors: Laure Elkrief, José Ferrusquia‐Acosta, Audrey Payancé, Lucile Moga, Luis Tellez, Michael Praktiknjo, Bogdan Procopet, Oana Farcau, Victor De Lédinghen, Rustam Yuldashev, Nicolas Tabchouri, Louise Barbier, Jérôme Dumortier, Benjamin Menahem, Marta Magaz, Virginia Hernández‐Gea, Agustin Albillos, Jonel Trebicka, Laurent Spahr, Andrea De Gottardi, Aurélie Plessier, Dominique Valla, Laura Rubbia‐Brandt, Christian Toso, Christophe Bureau, Juan‐Carlos Garcia‐Pagan, Pierre‐Emmanuel Rautou
Journal: Hepatology (2019)

In patients with idiopathic noncirrhotic portal hypertension (INCPH), data on morbidity and mortality of abdominal surgery are scarce. We retrospectively analyzed the charts of patients with INCPH undergoing abdominal surgery within the Vascular Liver Disease Interest Group network. Forty‐four patients with biopsy‐proven INCPH were included. Twenty‐five (57%) patients had one or more extrahepatic conditions related to INCPH, and 16 (36%) had a history of ascites. Forty‐five procedures were performed, including 30 that were minor and 15 major. Nine (20%) patients had one or more Dindo‐Clavien grade ≥ 3 complication within 1 month after surgery. Sixteen (33%) patients had one or more portal hypertension–related complication within 3 months after surgery. Extrahepatic conditions related to INCPH ( P = 0.03) and history of ascites ( P = 0.02) were associated with portal hypertension–related complications within 3 months after surgery. Splenectomy was associated with development of portal vein thrombosis after surgery ( P = 0.01). Four (9%) patients died within 6 months after surgery. Six‐month cumulative risk of death was higher in patients with serum creatinine ≥ 100 μmol/L at surgery (33% versus 0%, P &lt; 0.001). An unfavorable outcome (i.e., either liver or surgical complication or death) occurred in 22 (50%) patients and was associated with the presence of extrahepatic conditions related to INCPH, history of ascites, and serum creatinine ≥ 100 μmol/L: 5% of the patients with none of these features had an unfavorable outcome versus 32% and 64% when one or two or more features were present, respectively. Portal decompression procedures prior to surgery (n = 10) were not associated with postoperative outcome. Conclusion : Patients with INCPH are at high risk of major surgical and portal hypertension–related complications when they harbor extrahepatic conditions related to INCPH, history of ascites, or increased serum creatinine.
Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study
Authors: Elise van Mulligen, Pascal Hendrik Pieter de Jong, Tjallingius Martijn Kuijper, Myrthe van der Ven, Cathelijne Appels, Casper Bijkerk, Joop B Harbers, Yael de Man, T H Esmeralda Molenaar, Ilja Tchetverikov, Yvonne P M Goekoop-Ruiterman, Jende van Zeben, Johanna M W Hazes, Angelique E A M Weel, Jolanda J Luime
Journal: Annals of the Rheumatic Diseases (2019)

Objectives The aim of this study is to evaluate the effectiveness of two tapering strategies after achieving controlled disease in patients with rheumatoid arthritis (RA), during 1 year of follow-up. Methods In this multicentre single-blinded (research nurses) randomised controlled trial, patients with RA were included who achieved controlled disease, defined as a Disease Activity Score (DAS) ≤ 2.4 and a Swollen Joint Count (SJC) ≤ 1, treated with both a conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and a TNF inhibitor. Eligible patients were randomised into gradual tapering csDMARDs or TNF inhibitors. Medication was tapered if the RA was still under control, by cutting the dosage into half, a quarter and thereafter it was stopped. Primary outcome was proportion of patients with a disease flare, defined as DAS &gt; 2.4 and/or SJC &gt; 1. Secondary outcomes were DAS, European Quality of Life-5 Dimensions (EQ5D) and functional ability (Health Assessment Questionnaire Disability Index [HAQ-DI]) after 1 year and over time. Results A total of 189 patients were randomly assigned to tapering csDMARDs (n = 94) or tapering anti-TNF (n = 95). The cumulative flare rates in the csDMARD and anti-TNF tapering group were, respectively, 33 % (95% CI,24% to 43 %) and 43 % (95% CI, 33% to 53 % (p = 0.17). Mean DAS, HAQ-DI and EQ-5D did not differ between tapering groups after 1 year and over time. Conclusion Up to 9 months, flare rates of tapering csDMARDs or TNF inhibitors were similar. After 1 year, a non-significant difference was found of 10 % favouring csDMARD tapering. Tapering TNF inhibitors was, therefore, not superior to tapering csDMARDs. From a societal perspective, it would be sensible to taper the TNF inhibitor first, because of possible cost reductions and less long-term side effects. Trial registration number NTR2754
Management Options for Gastric Variceal Hemorrhage
Authors: Edward Wolfgang Lee, Puja Shahrouki, Lourdes Alanis, Pengxu Ding, Stephen T. Kee
Journal: JAMA Surgery (2019)

<h3>Importance</h3> Varices are one of the main clinical manifestations of cirrhosis and portal hypertension. Gastric varices are less common than esophageal varices but are often associated with poorer prognosis, mainly because of their higher propensity to bleed. <h3>Observations</h3> Currently, treatments used to control and manage gastric variceal bleeding include β-blockers, endoscopic injection sclerotherapy, endoscopic variceal ligation, endoscopic variceal obturation, shunt surgery, transjugular intrahepatic portosystemic shunts, balloon-occluded retrograde transvenous obliteration (BRTO), and modified BRTO. In the past few decades, Western (United States and Europe) interventional radiologists have preferred transjugular intrahepatic portosystemic shunts that aim to decompress the liver and reduce portal pressure. Conversely, Eastern radiologists (Japan and South Korea) have preferred BRTO that directly targets the gastric varices. Over the past 20 years, BRTO has evolved and procedure-related risks have decreased. Owing to its safety and efficiency in treating gastric varices, BRTO is now starting to gain popularity among Western interventional radiologists. In this review, we present a comprehensive literature review of current and emerging management options, including BRTO and modified BRTO, for the treatment of gastric varices in the setting of cirrhosis and portal hypertension. <h3>Conclusions and Relevance</h3> Balloon-occluded retrograde transvenous obliteration has emerged as a safe and effective alternative treatment option for gastric variceal hemorrhage. A proper training, evidence-based consensus and guideline, thorough preprocedural and postprocedural evaluation, and a multidisciplinary team approach with BRTO and modified BRTO are strongly recommended to ensure best patient care.
Toward clinically applicable biomarkers for asthma: An <scp>EAACI</scp> position paper
Authors: Zuzana Diamant, Susanne Vijverberg, Kjell Alving, Arzu Bakirtas, Leif Bjermer, Adnan Custovic, Sven‐Erik Dahlen, Mina Gaga, Roy Gerth van Wijk, Stefano Del Giacco, Eckard Hamelmann, Liam G. Heaney, Enrico Heffler, Ömer Kalayci, Konstantinos Kostikas, Rene Lutter, Anna‐Carin Olin, Svetlana Sergejeva, Angela Simpson, Peter J. Sterk, Ellen Tufvesson, Ioana Agache, Sven F. Seys
Journal: Allergy (2019)

Inflammation, structural, and functional abnormalities within the airways are key features of asthma. Although these processes are well documented, their expression varies across the heterogeneous spectrum of asthma. Type 2 inflammatory responses are characterized by increased levels of eosinophils, FeNO, and type 2 cytokines in blood and/or airways. Presently, type 2 asthma is the best-defined endotype, typically found in patients with allergic asthma, but surprisingly also in nonallergic patients with (severe) asthma. The etiology of asthma with non-type 2 inflammation is less clear. During the past decade, targeted therapies, including biologicals and small molecules, have been increasingly integrated into treatment strategies of severe asthma. These treatments block specific inflammatory pathways or single mediators. Single or composite biomarkers help to identify patients who will benefit from these treatments. So far, only a few inflammatory biomarkers have been validated for clinical application. The European Academy of Allergy & Clinical Immunology Task Force on Biomarkers in Asthma was initiated to review different biomarker sampling methods and to investigate clinical applicability of new and existing inflammatory biomarkers (point-of-care) to support diagnosis, targeted treatment, and monitoring of severe asthma. Subsequently, we discuss existing and novel targeted therapies for asthma as well as applicable biomarkers.
Negative Pressure Wound Therapy for Surgical Site Infection Prevention Requires Further Study Before Widespread Adoption
Authors: Patrick Murphy, Tanya Kuper, Michael Ott
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Critically Ill Patients With The Middle East Respiratory Coronavirus (mers-Cov) Infection
Authors: Y M Arabi, H Balkhy, A Al-Omari, F M Al-Hameed, A Al-Aithan, A Abdulmomen, K Alkhatib, M Al-Ahmadi, J Whitehead, H Tamim, N Shindo, L Merson, R Fowler, F G Hayden
Journal: American Journal of Respiratory and Critical Care Medicine (2015)
Endoscopic ultrasound-guided salvage for a disconnected choledochojejunostomy anastomosis through a jejunal stoma
Authors: Tatsuya Sato, Yousuke Nakai, Tsuyoshi Hamada, Naminatsu Takahara, Suguru Mizuno, Hirofumi Kogure, Kazuhiko Koike
Journal: Endoscopy (2019)

A 25-year-old man with a history of deceased-donor liver transplantation using a right lobe graft with Roux-en-Y choledochojejunostomy was referred for endoscopic management of cholangitis due to anastomotic strictures [1] ([Fig. 1]). The patient developed postoperative bile leakage and disconnection of the choledochojejunostomy anastomosis. He underwent percutaneous transhepatic placement of catheters for the bile ducts in segments 5, 6, and 7 (B5 – 7). Re-canalization was achieved by percutaneous procedures for B5 and B6, whereas a complete disconnection between B7 and the jejunum was not amenable to the percutaneous approach or double-balloon endoscopy. Therefore, we decided to perform endoscopic ultrasound (EUS)-guided drainage to re-anastomose B7 with the jejunum.
Enhanced Programmed Death 1 and Diminished Programmed Death Ligand 1 Up‐Regulation Capacity of Post‐Activated Lupus B Cells
Authors: Ana‐Luisa Stefanski, Annika Wiedemann, Karin Reiter, Falk Hiepe, Andreia C. Lino, Thomas Dörner
Journal: Arthritis & Rheumatology (2019)

Objective To assess the expression of programmed death 1 ( PD ‐1), PD ligand 1 ( PD ‐L1), and PD ‐L2 by B cells from patients with systemic lupus erythematosus ( SLE ) at baseline and after in vitro stimulation and to analyze their functional relationship to B cell proliferation. Methods Peripheral blood mononuclear cells obtained from 29 SLE patients and 27 healthy donors were stimulated with interleukin‐2 ( IL ‐2)/ IL ‐10, anti–B cell receptor (anti‐ BCR ), CpG, and CD 40L alone or in combination. Expression of PD ‐1, PD ‐L1, and PD ‐L2 on defined B cell subsets as well as on CD 3+ T cells was analyzed by flow cytometry at baseline and after 48 hours of stimulation. Additionally, after 48 hours of stimulation, CD 71 was evaluated as a proliferation marker on CD 19+ CD 20+ B cells. Results Increased PD ‐1 expression was characteristic of unstimulated lupus B cells and T cells. Upon stimulation of B cells with IL ‐2/ IL ‐10, anti‐ BCR , CpG, and CD 40L for 48 hours, the capacity of SLE B cells to up‐regulate PD ‐L1 expression was substantially diminished ( P = 0.0006) along with reduced B cell proliferation ( P = 0.0039). Reduced PD ‐L1 expression was inversely correlated with the presence of the interferon signature (r = –0.8571, P &lt; 0.0001) and the clinical SLE Disease Activity Index score (r = –0.5696, P = 0.0087). Conclusion Post‐activated, hyporesponsive lupus B cells are characterized by a phenotype of increased PD ‐1, functionally diminished PD ‐L1 up‐regulation capacity, and reduced proliferation upon stimulation.
Treating Hepatitis C in Homeless Veterans at the Greater Los Angeles Veterans' Affairs Medical Center
Authors: Omar Bakr, Lillian Gelberg, Shinobu Seragaki, Sarah Youn, Jenna Kawamoto, Marcie Hoppe, Lisa Altman, Kristin Kopelson, Folasade P. May, Brianna Cowan, Debika Bhattacharya
Journal: Hepatology (2019)

Bakr, Omar; Gelberg, Lillian; Seragaki, Shinobu; Youn, Sarah; Kawamoto, Jenna; Hoppe, Marcie; Altman, Lisa; Kopelson, Kristin; May, Folasade P.; Cowan, Brianna; Bhattacharya, Debika Author Information
Corrigendum to: “Gold and gold-silver alloy nanoparticles enhance the myogenic differentiation of myoblasts through p38 MAPK signaling pathway and promote in vivo skeletal muscle regeneration” [Biomaterials 175(2018)19–29]
Authors: Juan Ge, Kai Liu, Wen Niu, Mi Chen, Min Wang, Yumeng Xue, Chuanbo Gao, Peter X Ma, Bo Lei
Journal: Biomaterials (2019)
Abstract 18738: Age- and Sex-Differences in British Columbia for Guideline-Directed Medical Therapy of Heart Failure
Authors: Omid Kiamanesh, Meijiao Guan, Yinshan Zhao, Karin H Humphries, Nathaniel M Hawkins, Sean A Virani, Mustafa Toma
Journal: Circulation (2017)

Introduction: Heart failure (HF) remains a major health burden in Canada despite the advent of effective guideline-directed medical therapy (GDMT). We describe age and sex differences in the adhere...
Antibodies in Development for Multiple Myeloma: A Systematic Review
Authors: Muhammad Asad Fraz, Muhammad Junaid Tariq, Muhammad Usman, Nadia Carenina Nunes Cavalcante Parr, Awais Ijaz, Malik Qistas Ahmad, Muhammad Yasir, Seren Durer, Muhammad Jahanzeb Khalil, Ceren Durer, Sharoon Samuel, Saher Nasir Amin, Ahmad Safdar, Faiz Anwer
Journal: Blood (2018)
Suicidal Attempts and Ideation Among Children and Adolescents in US Emergency Departments, 2007-2015
Authors: Brett Burstein, Holly Agostino, Brian Greenfield
Journal: JAMA Pediatrics (2019)

This cross-sectional analysis of the National Hospital Ambulatory Medical Care Survey studies emergency department visits for suicide attempts and suicidal ideation among US youth between 2007 and 2015.